-The Economic Times "Sedition" is a legal construct from less enlightened times, when the sovereign power claimed a divine sanction and subjects were expected to live in awe and fear. So what is republican India doing, in its seventh decade, in bringing a charge of sedition against a self-publishing cartoonist with a propensity for scatology and lurid imagery? A convulsive attack of folly that the agencies of the Indian state have...
More »SEARCH RESULT
Bt Brinjal is safe, claims NIN
-The Times of India HYDERABAD: Is Bt Brinjal safe? The demonisation of BT crops got a push with the parliamentary committee on agriculture in its report submitted last month commenting that transgenics in food crops would be fraught with unknown consequences. But the Hyderabad-based National Institute of Nutrition (NIN) of the Indian Council of Medical Research (ICMR) says that Bt Brinjal is safe. A voluminous report on the laboratory experiments carried out...
More »A judgement & some worries
-Live Mint The judgement whittles down an already embattled freedom available to the Press In an important judgement it delivered on Tuesday, the Supreme Court has institutionalized the power to temporarily prohibit the Press from reporting court proceedings in case it interferes with the right to a free and fair trial. While the court shied from prescribing guidelines for the Press on court reporting, in the same breath it allowed individuals and companies...
More »Government to assure, not insure, health--Vidya Krishnan and Anuja
-Live Mint NAC wants Rashtriya Swasthya Bima Yojna to be absorbed into new policy for universal health coverage The National Advisory Council (NAC), which sets the policy agenda for the Congress party led United Progressive Alliance (UPA) government, wants the Rashtriya Swasthya Bima Yojna (RSBY) insurance scheme to be absorbed into the new policy for universal health coverage (UHC), taking the latter closer to realization. This is part of the government’s bid to move...
More »Dengue still retains its deadly bite -R Prasad
-The Hindu Vaccine’s overall efficacy in a recent trial is ‘lower than expected’ The just concluded Phase IIb (proof-of-concept) dengue vaccine trial against all the four virus types (serotypes) that cause dengue has not only shown an unexpectedly low efficacy of 30.2 per cent but has also challenged many well-established hypotheses and ideas. The trial was conducted in about 4,000 children in the age group 4 and 11 in the dengue endemic district...
More »